Compare AU
Compare CURE vs. IHD
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the iShares S&P/ASX Div Opportunities Esg Screened ETF (IHD). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | IHD | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 83 | 27 |
Median incremental investment | $619.50 | $644.56 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,437.24 | $1,357.92 |
Average age group | > 35 | > 35 |
Key Summary
CURE | IHD | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | IHD.AX was created on 2010-12-06 by iShares. The fund's investment portfolio concentrates primarily on high dividend yield equity. The ETF currently has 305.98m in AUM and 51 holdings. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of 50 ASX listed stocks that offer high dividend yields while meeting diversification, profitability and tradability requirements as well as being screened for sustainability considerations |
Top 3 holdings | Natera Inc (3.33 %) Incyte Corp (2.95 %) Gilead Sciences Inc (2.81 %) | RIO TINTO LTD (9.87 %) FORTESCUE LTD (8.72 %) WESTPAC BANKING CORPORATION CORP (8.18 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Financials (42.51 %) Materials (22.84 %) Industrials (13.44 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | Australia (99.25 %) New Zealand (0.75 %) |
Management fee | 0.45 % | 0.23 % |
Key Summary
CURE | IHD | |
|---|---|---|
Issuer | Global X | iShares |
Tracking index | S&P Biotechnology Select Industry | S&P/ASX Dividend Opportunities Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.23 % |
Price | $52.68 | $14.64 |
Size | $36.301 million | $313.421 million |
10Y return | N/A | 2.23 % |
Annual distribution yield (5Y) | 4.24 % | 7.42 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 09/12/2010 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | IHD | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 83 | 27 |
Median incremental investment | $619.50 | $644.56 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,437.24 | $1,357.92 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | IHD | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | IHD |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |